Does the media favor CRSP or RXRX?

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 4 mentions for Recursion Pharmaceuticals. CRISPR Therapeutics' average media sentiment score of 0.60 beat Recursion Pharmaceuticals' score of 0.42 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RYTM or RXRX?

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 4 mentions for Recursion Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.73 beat Recursion Pharmaceuticals' score of 0.42 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SRRK or RXRX?

In the previous week, Scholar Rock had 21 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 25 mentions for Scholar Rock and 4 mentions for Recursion Pharmaceuticals. Scholar Rock's average media sentiment score of 0.77 beat Recursion Pharmaceuticals' score of 0.42 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 11 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RXRX or CGON?

In the previous week, CG Oncology had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 5 mentions for CG Oncology and 4 mentions for Recursion Pharmaceuticals. CG Oncology's average media sentiment score of 0.93 beat Recursion Pharmaceuticals' score of 0.42 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RXRX or MIRM?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 5 mentions for Mirum Pharmaceuticals and 4 mentions for Recursion Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.76 beat Recursion Pharmaceuticals' score of 0.42 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Recursion Pharmaceuticals (RXRX) Competitors

$3.24 -0.17 (-4.99%)

Closing price 04:00 PM Eastern

Extended Trading

$3.24 0.00 (0.00%)

As of 07:59 PM Eastern

Compare

RXRX vs. CRSP, RYTM, SRRK, CGON, and MIRM

Should you buy Recursion Pharmaceuticals stock or one of its competitors? Recursion Pharmaceuticals's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), CG Oncology (CGON), and Mirum Pharmaceuticals (MIRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Recursion Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 4 mentions for Recursion Pharmaceuticals. CRISPR Therapeutics' average media sentiment score of 0.60 beat Recursion Pharmaceuticals' score of 0.42 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CRISPR Therapeutics currently has a consensus target price of $68.06, suggesting a potential upside of 31.31%. Recursion Pharmaceuticals has a consensus target price of $8.06, suggesting a potential upside of 148.77%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

CRISPR Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,427.76	-$581.60M	-$4.76	N/A
Recursion Pharmaceuticals	$74.68M	23.23	-$644.76M	-$1.04	N/A

Recursion Pharmaceuticals has a net margin of -945.94% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Summary

CRISPR Therapeutics beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 4 mentions for Recursion Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.73 beat Recursion Pharmaceuticals' score of 0.42 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	34.95	-$196.54M	-$3.11	N/A
Recursion Pharmaceuticals	$74.68M	23.23	-$644.76M	-$1.04	N/A

Rhythm Pharmaceuticals currently has a consensus target price of $140.67, suggesting a potential upside of 45.36%. Recursion Pharmaceuticals has a consensus target price of $8.06, suggesting a potential upside of 148.77%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.75
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Rhythm Pharmaceuticals has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Summary

Rhythm Pharmaceuticals beats Recursion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Scholar Rock has higher earnings, but lower revenue than Recursion Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Recursion Pharmaceuticals	$74.68M	23.23	-$644.76M	-$1.04	N/A

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Scholar Rock presently has a consensus price target of $66.00, indicating a potential upside of 32.00%. Recursion Pharmaceuticals has a consensus price target of $8.06, indicating a potential upside of 148.77%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.94
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Scholar Rock has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

In the previous week, Scholar Rock had 21 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 25 mentions for Scholar Rock and 4 mentions for Recursion Pharmaceuticals. Scholar Rock's average media sentiment score of 0.77 beat Recursion Pharmaceuticals' score of 0.42 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	11 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Scholar Rock beats Recursion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to CG Oncology?

Recursion Pharmaceuticals (NASDAQ:RXRX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Recursion Pharmaceuticals currently has a consensus target price of $8.06, suggesting a potential upside of 148.77%. CG Oncology has a consensus target price of $87.78, suggesting a potential upside of 20.99%. Given Recursion Pharmaceuticals' higher possible upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Recursion Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

CG Oncology has lower revenue, but higher earnings than Recursion Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	23.23	-$644.76M	-$1.04	N/A
CG Oncology	$4.04M	1,591.79	-$160.99M	-$2.69	N/A

Recursion Pharmaceuticals has a net margin of -945.94% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, CG Oncology had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 5 mentions for CG Oncology and 4 mentions for Recursion Pharmaceuticals. CG Oncology's average media sentiment score of 0.93 beat Recursion Pharmaceuticals' score of 0.42 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CG Oncology beats Recursion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 5 mentions for Mirum Pharmaceuticals and 4 mentions for Recursion Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.76 beat Recursion Pharmaceuticals' score of 0.42 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -139.18% compared to Recursion Pharmaceuticals' net margin of -945.94%. Mirum Pharmaceuticals' return on equity of -36.28% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	23.23	-$644.76M	-$1.04	N/A
Mirum Pharmaceuticals	$521.31M	11.70	-$23.36M	-$14.55	N/A

Recursion Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Recursion Pharmaceuticals presently has a consensus price target of $8.06, indicating a potential upside of 148.77%. Mirum Pharmaceuticals has a consensus price target of $137.31, indicating a potential upside of 46.23%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.83B	$3.83B	$7.16B	$14.34B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	N/A	14.18	273.41	25.34
Price / Sales	23.23	1,542.12	674.92	98.63
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	1.51	15.19	10.38	6.20
Net Income	-$644.76M	-$22.78M	$3.49B	$358.18M
7 Day Performance	-5.81%	-2.55%	-2.20%	-1.61%
1 Month Performance	2.53%	0.29%	-0.38%	-3.62%
1 Year Performance	-32.08%	39.29%	19.16%	5.95%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	1.4704 of 5 stars	$3.24 -5.0%	$8.06 +148.8%	-29.4%	$1.83B	$74.68M	N/A	600
CRSP CRISPR Therapeutics	2.4924 of 5 stars	$55.79 -1.2%	$68.06 +22.0%	-5.9%	$5.46B	$11M	N/A	460	News Coverage Gap Down
RYTM Rhythm Pharmaceuticals	2.7756 of 5 stars	$102.74 -2.0%	$141.12 +37.4%	+6.5%	$7.19B	$239.92M	N/A	140	News Coverage Positive News Analyst Forecast Insider Trade
SRRK Scholar Rock	3.2662 of 5 stars	$55.33 -1.1%	$58.77 +6.2%	+63.7%	$6.81B	N/A	N/A	140	Trending News Analyst Forecast Gap Down
CGON CG Oncology	2.87 of 5 stars	$74.67 +0.5%	$83.18 +11.4%	+121.3%	$6.59B	$4.04M	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. CRSP, RYTM, SRRK, CGON, and MIRM

How does Recursion Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to Scholar Rock?

Summary

How does Recursion Pharmaceuticals compare to CG Oncology?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. CRSP, RYTM, SRRK, CGON, and MIRM

How does Recursion Pharmaceuticals compare to CRISPR Therapeutics?

Which has more volatility and risk, CRSP or RXRX?

Does the media favor CRSP or RXRX?

Do insiders and institutionals have more ownership in CRSP or RXRX?

Do analysts recommend CRSP or RXRX?

Which has better earnings and valuation, CRSP or RXRX?

Is CRSP or RXRX more profitable?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Do insiders & institutionals believe in RYTM or RXRX?

Does the media prefer RYTM or RXRX?

Which has higher valuation and earnings, RYTM or RXRX?

Do analysts rate RYTM or RXRX?

Which has more volatility and risk, RYTM or RXRX?

Is RYTM or RXRX more profitable?

Summary

How does Recursion Pharmaceuticals compare to Scholar Rock?

Which has stronger earnings and valuation, SRRK or RXRX?

Which has more volatility & risk, SRRK or RXRX?

Do analysts prefer SRRK or RXRX?

Do insiders & institutionals have more ownership in SRRK or RXRX?

Is SRRK or RXRX more profitable?

Does the media prefer SRRK or RXRX?

Summary

How does Recursion Pharmaceuticals compare to CG Oncology?

Do analysts prefer RXRX or CGON?

Which has more volatility & risk, RXRX or CGON?

Which has better earnings and valuation, RXRX or CGON?

Is RXRX or CGON more profitable?

Does the media refer more to RXRX or CGON?

Do institutionals and insiders hold more shares of RXRX or CGON?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Does the media prefer RXRX or MIRM?

Is RXRX or MIRM more profitable?

Do insiders & institutionals believe in RXRX or MIRM?

Which has higher valuation and earnings, RXRX or MIRM?

Which has more volatility & risk, RXRX or MIRM?

Do analysts prefer RXRX or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools